

## Anaesthesia recommendations for **Transverse myelitis**

**Disease name:** Transverse myelitis

**ICD 10:** G37.3

**Synonyms:** -

**Disease summary:** Transverse myelitis (TM) refers to a group of inflammatory spinal cord disorders with motor, sensory, and autonomic dysfunction [1,2]. It has an incidence of up to 8 in 1 000 000, with a bimodal age predilection in in the second and fourth decades of life [2,3]. Females and males are equally affected [4]. Approximately one third of cases are idiopathic, but it also may arise in association with infections, drug/toxin exposure, or underlying autoimmune disorders including multiple sclerosis. TM has occasionally been attributed to neuraxial anaesthesia [5-10]. and general anaesthesia [11]. The condition is characterised by accumulation of inflammatory cells in a localised region of spinal cord, with focal demyelination.

TM presents with a well-demarcated sensory level corresponding to the site of the spinal cord lesion, with associated weakness of distal spinal cord segments as well as bowel and bladder dysfunction [2,4]. The level of the lesion is most often in the thoracic or cervical spine. Neuropathic pain and allodynia are also common. Deficits are usually bilateral. The time from symptom onset to clinical nadir is usually within 3 weeks. An acute period of flaccid paralysis lasting up to 6 weeks is followed by the onset of upper motor neuron symptoms such as spasticity and hyper-reflexia. Autonomic dysreflexia and orthostatic hypotension have also been described [1].

In the acute phase, patients may be treated with systemic corticosteroids, intravenous immunoglobulin, plasma exchange, or immunomodulating medications (i.e., mitoxantrone, methotrexate, mycophenolate, rituximab, azathioprine, cyclophosphamide) [1,12,13]. Neurologic recovery predominantly occurs in the first 3 months after presentation, but many patients have a protracted course over years [2,4]. Up to 25% of patients experience a recurrence of TM. Only one third of patients fully recover without residual sequelae [3].

---

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong

---



Find more information on the disease, its centres of reference and patient organisations on Orphanet: [www.orpha.net](http://www.orpha.net)

---

### **Typical surgery**

---

For prolonged respiratory insufficiency, tracheostomy may be required. Patients with TM may require surgery for similar indications as the general population.

---

### **Type of anaesthesia**

---

There are few published care reports of anaesthetic management in TM. General anaesthesia with balanced anaesthetic maintenance is typically preferred. Epidural and spinal anaesthesia have been occasionally reported [14,15].

As with other neurologic disorders, the use of neuraxial anaesthesia or peripheral nerve blocks is not strictly contraindicated, though the relative risks and benefits of these approaches should be carefully weighed [16].

---

### **Necessary additional pre-operative testing (beside standard care)**

---

Careful neurologic examination and detailed documentation of sensory and motor deficits is required. Prior history of autonomic dysreflexia episodes should be elicited, along with their triggers and symptoms, such as flushing, headache, diaphoresis, and hypertension.

Complete blood count, coagulation profile, type and screen should be obtained, as should standard liver and renal function tests.

---

### **Particular preparation for airway management**

---

Gastroparesis and constipation may be seen in TM, possibly placing them at risk for aspiration. Rapid sequence induction should be considered.

---

### **Particular preparation for transfusion or administration of blood products**

---

Patients with acute TM may be treated by plasma exchange.

Otherwise, no special considerations for blood product transfusion or administration.

---

### **Particular preparation for anticoagulation**

---

Prophylactic anticoagulation is recommended when patients have limited mobility, and this may impact the patients' eligibility for certain regional anaesthesia techniques.

## **Particular precautions for positioning, transportation and mobilisation**

---

Patients with residual neurologic dysfunction after acute TM may be liable to spasticity, osteoporosis, and pressure ulcers, so careful positioning and padding are essential [1].

## **Interactions of disease and anaesthesia medications**

---

It is controversial whether patients acutely affected by or recovered from TM are at risk for disease recurrence when neuraxial anaesthesia is administered. Thus, the risks and benefits of epidural or spinal anaesthesia should be considered carefully.

As in other denervation injuries, administration of succinylcholine may be associated with significant hyperkalaemia, so this must be avoided, starting 24 to 48 hours after onset of the injury. It is unclear when succinylcholine may be used again safely after the acute phase of TM, but a period of at least one year seems prudent [17]. Patients with TM are sensitive to the effects of non-depolarising neuromuscular blocking agents and may have prolonged weakness after a single induction dose, therefore, these medications should be used judiciously. It is essential to employ neuromuscular monitoring to guide the use of paralytics. Sugammadex may be given to ensure complete reversal of muscle strength.

## **Anaesthetic procedure**

---

There are few published case reports of anaesthetic management in patients with TM [18].

General anaesthesia has been described, using standard intravenous induction agents: propofol, thiopental, non-depolarising neuromuscular blocking agents, opioids, and lidocaine. Balanced anaesthesia maintenance with volatile anaesthetics, nitrous oxide, and intravenous opioids is effective. Endotracheal intubation is most commonly utilised, but supraglottic airways have also been described [19]. Maintenance of spontaneous breathing and avoidance of paralytics may be considered.

It is unclear whether neuraxial anaesthesia exacerbates TM. One benefit of neuraxial anaesthesia is avoidance of autonomic dysreflexia in patients with complete loss of spinal cord function below their level of injury, and this should be weighed against the potential risk of inciting additional neurologic damage. Other regional anaesthesia techniques should similarly be considered in light of relative potential benefits and risks.

## **Particular or additional monitoring**

---

Neuromuscular monitoring is essential when patients require neuromuscular blocking agents. Other standard anaesthetic monitors should be used as appropriate (e.g., electrocardiogram, non-invasive blood pressure, pulse oximetry, capnography, gas analyser).

Invasive blood pressure monitoring should be considered when patients are at risk for autonomic dysreflexia.

---

## Possible complications

---

Because patients with TM are treated acutely with high-dose corticosteroids, adrenal insufficiency should be considered in the event of perioperative haemodynamic instability. Liver dysfunction may be seen with administration of immunomodulatory medications used in TM.

The presence of neurogenic shock in the early course of the condition may cause hypotension and bradycardia.

Functional spinal cord transection above T6 may predispose patients to autonomic dysreflexia with resultant severe hypertension [20]. Autonomic dysreflexia has been reported as early as 72 hours after spinal cord injury and is due to a loss of descending inhibition over sympathetic spinal cord reflexes distal to the spinal cord lesion. Episodes are precipitated by nociceptive stimuli below the sensory level. The severe hypertension associated with autonomic dysreflexia may lead to intracranial haemorrhage and death, if left uncontrolled.

---

## Post-operative care

---

Post-operative neurologic examination and documentation is recommended, particularly if there is subjective complaint of changes in neurologic status from baseline.

Patients with respiratory insufficiency may need prolonged post-operative ventilatory support in the intensive care unit.

---

## Disease-related acute problems and effect on anaesthesia and recovery

---

Autonomic dysreflexia, adrenal insufficiency, respiratory insufficiency, and sensitivity to non-depolarising neuromuscular blocking agents, as described previously. Avoidance of succinylcholine may be necessary.

---

## Ambulatory anaesthesia

---

Patients fully recovered from TM can likely safely undergo ambulatory anaesthesia. The degree of residual neurologic dysfunction should be considered, as should the time since recovery from TM.

---

## Obstetrical anaesthesia

---

It is unclear whether pregnancy has any effect on TM. There are few reports of obstetrical anaesthesia care for patients with TM. Patients with ongoing sensory loss may not be able to detect uterine contractions, while labour progression and contractions may trigger autonomic dysreflexia.

General anaesthesia is the most common approach [14,18,20,21]. Standard aspiration precautions for pregnant patients should be observed (e.g., non-particulate antacid, H<sub>2</sub>-receptor antagonist, metoclopramide, proton-pump inhibitor, rapid sequence induction, cricoid

pressure). Additional airway adjuncts should be available given dynamic airway changes during labour and poor maternal apnoea tolerance.

Effective neuraxial analgesia and anaesthesia can mitigate the risk of autonomic dysreflexia during labour or caesarean delivery, and may outweigh the theoretical risk of exacerbating TM [22,23]. While neuraxial anaesthesia has been safely performed in patients with TM and other demyelinating diseases (e.g., multiple sclerosis), this practice remains controversial and should be considered carefully.

One case report described caesarean delivery with ketamine sedation alone, for a patient with TM who was insensate up to T8 [2,4]. However, this approach is not generally recommended.

## References

1. Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. *Neurol Clin* 2013;31:79–138. DOI:10.1016/j.ncl.2012.09.008
2. Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. *N Engl J Med* 2010; 363:564–572. DOI:10.1056/NEJMcp1001112
3. Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. *Autoimmun Rev* 2010;9:A395–A399. DOI:10.1016/j.autrev.2009.12.007
4. Borchers AT, Gershwin ME. Transverse myelitis. *Autoimmun Rev* 2012;11:231–248. DOI: 10.1016/j.autrev.2011.05.018
5. Hsu M-C, Hung M-H, Chen J-S, Cheng Y-J. Acute transverse myelitis after thoracic epidural anesthesia and analgesia: Should anesthesia and analgesia be blamed? *Acta Anaesthesiol Taiwan* 2013;51:37–39. DOI:10.1016/j.aat.2013.03.001
6. Kitazaki Y, Ueno A, Maeda K, et al. A case of longitudinally extensive transverse myelitis with an isolated pontine lesion following epidural and spinal anesthesia for cesarean section. *eNeurologicalSci* 2020;21:100264. DOI: 10.1016/j.ensci.2020.100264
7. Martinez-Garcia E, Pelaez E, Roman JC, Perez-Gallardo A. Transverse myelitis following general and epidural anaesthesia in a paediatric patient. *Anaesthesia* 2005;60:921–923. DOI:10.1111/j.1365-2044.2005.04256.x
8. Shimada T, Yufune S, Tanaka M, Akai R, Satoh Y, Kazama T. Acute transverse myelitis arising after combined general and thoracic epidural anesthesia. *JA Clin Rep* 2015;1:4. DOI:10.1186/s40981-015-0006-5
9. Lucas DN, Kennedy A, Dob DP. Dural puncture and iatrogenic pneumocephalus with subsequent transverse myelitis in a parturient. *Can J Anaesth* 2000;47:1103–1106. DOI:10.1007/BF03027963
10. Seok JH, Lim YH, Woo SH, Yon JH. Transverse myelitis following combined spinal- epidural anesthesia. *Korean J Anesthesiol.* 2012;63:473–474. DOI:10.4097/kjae.2012.63.5.473
11. Gutowski NJ, Davies AO. Transverse myelitis following general anaesthesia. *Anaesthesia* 1993;48:44–45. DOI:10.1111/j.1365-2044.1993.tb06790.x
12. Balakrishnan IM, Yadav N, Singh GP, Prabhakar H. Anaesthetic considerations in patients with transverse myelitis. *Southern African J Anaesth and Analg* 2014;19:323–324. DOI:10.1080/22201173.2013.10872949
13. Krishnan C, Kaplin AI, Pardo CA, Kerr DA, Keswani SC. Demyelinating disorders: update on transverse myelitis. *Curr Neurol Neurosci Rep* 2006;6:236–243. DOI:10.1007/s11910-006-0011-1
14. Thomas S, Massey S, Douglas J, Magee L, Rosengarten M. Obstetric anaesthesia and transverse myelitis. *Int J Obstet Anesth* 2010;19:467–468. DOI:10.1016/j.ijoa.2010.06.008
15. Ferrer-Zaccaro LE, Triana C, Pérez-Zauner AM. Anestesia para cesárea en paciente con mielitis transversa. *Rev Mex de Anestesiología* 2011;34:126–130
16. Hebl JR, Horlocker TT, Schroeder DR. Neuraxial anesthesia and analgesia in patients with preexisting central nervous system disorders. *Anesth Analg* 2006;103:223–228. DOI:10.1213/01.ane.0000220896.56427.53
17. Martyn J, Durieux ME. Succinylcholine: new insights into mechanisms of action of an old drug. *Anesthesiology* 2006;104:633–634. DOI:10.1097/00000542-200604000-00004
18. Hunter S, Katz D, Riley K, Anderson M. Anaesthesia for an emergent caesarean section in a patient with acute transverse myelitis. *J Obstet Anaesth Crit Care* 2018;8:58. DOI: 10.4103/joacc.JOACC\_45\_17
19. Larsen MC. Anesthetic management of an adult patient with transverse myelitis. *Int Stud J Nurse Anes* 2016;15:47–50
20. Walsh P, Grange C, Beale N. Anaesthetic management of an obstetric patient with idiopathic acute transverse myelitis. *Int J Obstet Anesth* 2010;19:98–101 DOI:10.1016/j.ijoa.2009.04.008
21. Weekes G, Hayes N, Bowen M. Reversal of prolonged rocuronium neuromuscular blockade with sugammadex in an obstetric patient with transverse myelitis. *Int J Obstet Anesth* 2010; 19:333–336. DOI:10.1016/j.ijoa.2010.03.009
22. Berghella V, Spector T, Trauffer P, Johnson A. Pregnancy in patients with preexisting transverse myelitis. *Obstet Gynecol* 1996;87:809–812
23. Lukovic E, Mankowitz SKW. Transverse Myelitis. In: *Consults in Obstetric Anesthesiology*. Vol 31. Cham: Springer International Publishing; 2018:625–627. DOI:10.1007/978-3-319-59680-8\_167

24. Saxena K, Kaul A, Shakir M. Anesthetic management of an obstetric patient with idiopathic transverse myelitis: A unique approach! J Obstet Anaesth Crit Care 2019;9:99.  
DOI: 10.4103/joacc.JOACC\_24\_19.

---

**Date last modified:**            **October 2021**

---

*This recommendation was prepared by:*

### **Authors**

**Mike Wong**, Anaesthesiologist, Department of Anaesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA  
michaelwong@som.umaryland.edu

**Seung Choi**, Anaesthesiologist, Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA

**Shobana Bharadwaj**, Anaesthesiologist, Department of Anaesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA

**Jessica Galey**, Anaesthesiologist, Department of Anaesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA

**Disclosure** The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

*This recommendation was reviewed by:*

### **Reviewers**

**Carlos R. Degrandi Oliveira**, Anaesthesiologist, H Hospital Guilherme Álvaro, Santos, Brasil  
degrandi@gmail.com

**Martin Jöhr**, Anaesthesiologist, Adlingenswil, Switzerland  
joehrmartin@bluewin.ch

**Disclosure** The reviewers have no financial or other competing interest to disclose.

*Please note that this recommendation has not been reviewed by an anaesthesiologist and a disease expert but by two anaesthesiologists instead.*

---